This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
Soligenix advances Phase 3 CTCL trial with interim analysis expected Q2 2026. Company secures orphan drug designation for dusquetide in Behcet's Disease, strengthening rare disease pipeline. #RareDiseases #Biotech
2026-05-15T05:39:37.674Z